8 CFU/ml were 2.81 to 66.5 times greater than the EC 50 s at 10 6 CFU/ml (median, 10.7-fold increase; P ‫؍‬ 0.002). These promising results indicate that ceftolozane-tazobactam achieves bactericidal activity against a wide range of ␤-lactamase-producing E. coli strains.
T
he rising prevalence of multidrug-resistant (MDR) Gramnegative organisms has forced urgent efforts to expand the therapeutic armamentarium against these problematic pathogens. Recent endeavors to develop new cephalosporin compounds exhibiting promising antipseudomonal activity led to the discovery of ceftolozane (ceftolozane, previously designated CXA-101 or FR264205) (1) . This novel agent has been credited with enhanced stability to popular chromosomally mediated cephalosporin resistance mechanisms (including hyperexpression of AmpC ␤-lactamase enzymes and efflux pumps) (2) , with a low propensity for cross-resistance to other cephalosporins to arise (3) .
Antimicrobial inactivation arising from transferable plasmidmediated ␤-lactamase hydrolysis presents the principal basis of ␤-lactam resistance among Enterobacteriaceae. More than 850 structurally diverse ␤-lactamase enzymes have been identified to date and classified as groups A to D based on their amino acid sequence homology (4) . Worryingly, the rapid emergence of extended-spectrum-␤-lactamase-producing Escherichia coli strains in recent times has been implicated in community-onset infections as a significant cause of morbidity, mortality, and health care-related costs. Despite ceftolozane's intrinsic benefits over other cephalosporins, the inability of the compound to overcome extended-spectrum ␤-lactamases (ESBLs) has been documented (5-7). To ameliorate this deficiency, the addition of the ␤-lactamase inhibitor tazobactam to ceftolozane extends the spectrum of activity of ceftolozane (8) . The resulting ceftolozane-tazobactam combination was found to display remarkable activity against a range of MDR Gram-negative species (7) and was subsequently approved by the Food and Drug Administration to treat complicated intra-abdominal and urinary tract infections in adults (9) .
Although the activity of ceftolozane-tazobactam against E. coli has been characterized in prior in vitro studies (10) (11) (12) , a systematic analysis of the combination's performance against strains producing different ␤-lactamases has yet to be investigated at multiple levels of bacterial burden. Therefore, integrating antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD) to effectively evaluate the bacteriologic response to ceftolozane-tazobactam is warranted (13) . Our objective was to utilize time-kill studies to characterize the bacterial killing effects of ceftolozane and tazobactam alone and in combination against different ␤-lactamase-producing E. coli strains.
MATERIALS AND METHODS
Bacterial strains. The four isogenic strains of E. coli employed for this study were engineered by Merck & Co. to differentially express a single ␤-lactamase; these included (i) 2805 (wild type, no ␤-lactamase), (ii) 2890 (AmpC ␤-lactamase), (iii) 2842 (CMY-10 ␤-lactamase), and (iv) 2807 (CTX-M-15 ␤-lactamase) ( ] and insertion sequence IS26 TnpA, Genbank no. GQ274933.1), insertion into a pBR322 cloning vector (GenBank no. J0749), and replacement of the bla TEM-1 open reading frame in the ␤-lactamase-deficient E. coli DH10B parent strain. The native bla TEM-1 promoter was included in the modified pBR322 plasmid to regulate the expression of the desired ␤-lactamase. Prior to experiments, subculture of 2805 was performed on tryptic soy agar (TSA) with 5% sheep blood (BD Biosciences, Franklin Lakes, NJ), while 2890, 2842, and 2807 were subcultured in the presence of 25 g/ml tetracycline to maintain the selection of plasmids.
Antibiotics, susceptibility testing, and medium. Analytical-grade ceftolozane and tazobactam powders were obtained from Merck & Co. (Kenilworth, NJ). Fresh stock solutions were prepared immediately prior to experiments in Milli-Q water. Standard broth microdilution methods were adopted from the Clinical and Laboratory Standards Institute (CLSI) (14) for the determination of MICs. The MIC experiments were performed in quadruplicate, while time-kill experiments were performed in duplicate; all studies were conducted using cation-adjusted Mueller-Hinton broth (CaMHB, at 25.0 mg/liter Ca 2ϩ and 12.5 mg/liter Mg 2ϩ ; Difco, Detroit, MI).
Time-kill experiments. Time-kill experiments were performed for ceftolozane and tazobactam alone and in combination, using previously described methods (15) . Briefly, fresh bacterial colonies from overnight growth were added to CaMHB to provide a bacterial suspension, which was diluted with CaMHB to achieve the desired starting inoculum of ϳ10 6 or ϳ10
8 CFU/ml in a 50-ml Falcon tube. A 6 by 5 array of ceftolozane (0, 1, 4, 16, 64, and 256 mg/liter) and tazobactam (0, 1, 4, 16, and 64 mg/liter) concentrations was tested as monotherapy and in combination over a period of 48 h. Thus, 30 treatment regimens were examined in total against each strain at both starting inocula. The choice of studied concentrations was based on clinically achievable targets discerned from freedrug PK profiles in healthy volunteers (16) .
Samples were withdrawn at 1, 2, 4, 8, 24, 26, 28, 32 , and 48 h after dosing. Colony counts were performed by plating 50-l aliquots of each diluted sample onto tryptic soy agar (TSA) plates containing 5% sheep blood (Becton Dickinson, Franklin Lakes, NJ) using an automated spiral dispenser (Whitley automatic spiral plater; Don Whitley Scientific Limited, West Yorkshire, England). Plates were incubated at 37°C for 24 h, and viable bacterial counts were determined (log 10 CFU/ml) using a laser bacteria colony counter (ProtoCOL version 2.05.02; Synbiosis, Cambridge, England). Bactericidal activity (99.9% kill) was associated with a Ն3.0-log 10 CFU/ml decrease in bacterial density compared to the initial inoculum at any time. Experiments were conducted over 48 h (as opposed to the traditional 24-h standard) to provide insight into the pharmacodynamics of each combination beyond 24 h, and also to better discriminate between the killing activities of the different ceftolozane and tazobactam concentrations. As the degradation of ceftolozane and tazobactam at 35°C was of concern, concentrations of ceftolozane and tazobactam were measured in the absence of bacteria over 48 h to calculate the rate of degradation for each agent.
Pharmacodynamic analyses. The bacterial killing effect (E) of monoand combination therapies was quantified as the log ratio change in bacterial density (CFU/ml) at 48 h versus preantibiotic exposure at 0 h (see equation 1) (17) . Point-based analyses were performed on plots of E versus ceftolozane concentrations. Taking into consideration the general mechanism of action of ␤-lactam-␤-lactam inhibitor combinations (whereby inhibitors are understood to bind to inactivating ␤-lactamase enzymes, thus allowing ␤-lactam agents to exert their action), we attributed the majority of the killing activity exerted by the ceftolozane-tazobactam combination to the effect of ceftolozane. Consequently, using nonlinear regression, concentration-effect relationships were fit to Hilltype models for each strain at each fixed tazobactam concentration, according to equation 2, where E 0 is the measured effect in the absence of ceftolozane, E max is the maximal effect, C is the concentration of ceftolozane, EC 50 is the concentration at which there is a 50% maximal effect, and H is the Hill constant. Statistical analyses of E max and EC 50 parameters were conducted to determine the effect of increasing tazobactam concentrations, using a nonparametric Friedman two-way analysis of variance (ANOVA) with pairwise comparisons (P Ͻ 0.05). Differences in parameter estimates at 10 6 versus 10 8 CFU/ml were determined using hypothesis testing (P Ͻ 0.05, F-test). All PD analyses and statistical evaluations were performed using Systat (version 13.00.05; Systat Software, IL).
Log ratio change ϭ Log 10 CFU 49 h CFU 0 h (1)
RESULTS
MICs and degradation rates. The ceftolozane MICs of each strain without tazobactam and in combination with 4 mg/liter tazobactam are presented in Table 1 . In the absence of tazobactam, the wild-type non-␤-lactamase-producing strain 2805 exhibited the lowest MIC, at 0.25 mg/liter. Strains 2890 and 2842 producing class C ␤-lactamases exhibited MICs of 4 and 8 mg/liter, respectively, while high resistance to ceftolozane was displayed by the CTX-M-15-producing strain, 2807, with an MIC of Ͼ128 mg/ liter. In the presence of 4 mg/liter tazobactam (per CLSI guidelines [14] ), the MICs of all ␤-lactamase-producing strains were reduced to 2-to 16-fold. After 48 h of incubation at 35°C, the degradation rate constants of ceftolozane ranged from 0.00466 to 0.00679 h Ϫ1 (half-life range, 102 to 148 h; R 2 Ն 0.938). Tazobactam concentrations were constant for the duration of the 48-h experiments.
Time-kill experiments. Time-kill profiles illustrating the change in bacterial density of the four E. coli strains following exposure to ceftolozane alone and in combination with tazobactam are presented according to fixed tazobactam concentrations at both 10 6 and 10 8 CFU/ml in Fig. 1 and 2 , respectively). Strain 2805 (no ␤-lactamase). For the susceptible strain 2805 at 10 6 CFU/ml, complete bactericidal activity reaching undetect- able limits of eradication was achieved within 24 h in response to monotherapy with 4 mg/liter ceftolozane (Ϫ6.48 log 10 CFU/ml, Fig. 1A ). No improvement in activity was gained at higher concentrations or in combination with tazobactam ( Fig. 1B to E) . At 10 8 CFU/ml, bactericidal activity was attained at low tazobactam concentrations (0 to 4 mg/liter) in combination with ceftolozane at Ն64 mg/liter (Ϫ6.43 to Ϫ8.33 log 10 CFU/ml; Fig. 2A to E ), or at higher tazobactam concentrations of Ն16 mg/liter in combination with Ն16 mg/liter ceftolozane (Ϫ5.32 to Ϫ8.23 log 10 CFU/ ml; Fig. 2D and E).
Strain 2890 (AmpC). Rapid activity was demonstrated with ceftolozane monotherapy at concentrations of 4 to 256 mg/liter against 2890 at 10 6 CFU/ml, with a decrease of Ϫ2.39 to Ϫ3.53 log 10 CFU/ml after 4 h, followed by regrowth, whereby bacterial counts mimicked those of the untreated control within 24 h (Fig.  1F) . A concentration-dependent trend toward a greater level of ceftolozane killing was observed in combination with increasing tazobactam concentrations. After 48 h, sustained bactericidal activity was attained with combinations of Ն4 mg/liter ceftolozane and Ն16 mg/liter tazobactam (Ϫ3.93 to Ϫ6.33 log 10 CFU/ml, Fig.  1I and J). At 10 8 CFU/ml, both monotherapy and combination regimens containing Յ4 mg/liter ceftolozane were mostly inactive (below Ϫ0.5 log 10 CFU/ml), while bacterial counts were reduced to undetectable limits with all regimens containing ceftolozane concentrations of 256 mg/liter (Fig. 2F to J) . Bactericidal activity at 48 h was noted for 64 mg/liter ceftolozane in combination with Ն4 mg/liter tazobactam (Ϫ4.01, Ϫ5.65, and Ϫ5.18 log 10 CFU/ml, Fig. 2H to J, respectively). The arm with 16 mg/liter ceftolozane was capable of achieving bactericidal activity at 48 h when in the presence of 16 and 64 mg/liter tazobactam (Ϫ3.12 and Ϫ4.09 log 10 CFU/ml, respectively).
Strain 2842 (CMY-10). Concentration-dependent enhancement of ceftolozane activity in combination with tazobactam was similarly observed for strain 2842 at 10 6 CFU/ml (Fig. 1K to O) . Accordingly, at Յ4 mg/liter tazobactam, activity was negligible in combination with 1 mg/liter ceftolozane, while bactericidal activity was noted within 8 h of exposure to 4 mg/liter ceftolozane (Ϫ2.94 to 3.23 log 10 CFU/ml) and was followed by rapid regrowth by 24 h (Fig. 1K to M) . However, bacteria were driven below detectable limits by all monotherapy and combination regimens containing Ն16 mg/liter ceftolozane (Ϫ6.18 log 10 CFU/ml; Fig.  1K to O). At 10 8 CFU/ml, substantial activity at Յ16 mg/liter tazobactam was seen in combination with Ն64 mg/liter ceftolozane (Ϫ2.28 to Ϫ5.18 log 10 CFU/ml; Fig. 2K to N) . At the highest tazobactam concentration of 64 mg/liter, bactericidal activity was achieved with Ն16 mg/liter ceftolozane (Ϫ4.74 to Ϫ5.39 log 10 CFU/ml; Fig. 2O ).
Strain 2807 (CTX-M-15). Strain 2807 was resistant to all ceftolozane monotherapy regimens at both inocula, with bacterial counts mirroring the control strain after 48 h. Interestingly, tazobactam maintained the ability to enhance activity in a concentration-dependent manner ( Fig. 1 and 2P to T, 10 6 and 10 8 CFU/ml, respectively). Against both inocula, ceftolozane concentrations of Ն64 mg/liter achieved bactericidal activity at 48 h at a tazobactam concentration of 16 mg/liter ( Fig. 1S and 2S , at or above Ϫ4.24 and Ϫ3.07 log 10 CFU/ml, respectively). In the presence of 64 mg/liter tazobactam, ceftolozane concentrations of Ն4 mg/liter achieved bactericidal activity at 48 h against the 10 6 CFU/ml inoculum (Fig. 1T , at or above Ϫ3.97 log 10 CFU/ml), whereas ceftolozane concentrations of Ն16 mg/liter were required for bactericidal activity against the 10 8 CFU/ml inoculum (Fig. 2T , at or above Ϫ3.66 log 10 CFU/ml).
PK/PD analyses. PK/PD analyses of time-kill data were performed to determine the target concentrations of ceftolozane and tazobactam associated with optimal activity. PD relationships were fit to a sigmoidal Hill-type function (equation 2), from which PD parameters were estimated (R 2 Ͼ 0.882, Table 2 ). The ceftolozane-tazobactam PD relationship was primarily defined by E max and EC 50 parameters, which provide a measure of the maximal capacity of efficacy and half-maximal potency, respectively. Across all strains at both inocula, no significant trends were noted in E max values with increasing tazobactam concentrations (P Ͼ 0.2, ANOVA). However, in the presence of tazobactam, a clear tendency toward lower EC 50 values was demonstrated for all strains at both inocula (Table 2) . Overall, pairwise comparisons revealed that all EC 50 differences at tazobactam concentrations of 0 to 4 mg/liter versus 16 and 64 mg/liter were statistically significant (P Ͻ 0.01, ANOVA). The changes in EC 50 as tazobactam concentrations increased from 0 to 4 mg/liter were not statistically significant, nor was the difference in EC 50 s at tazobactam concentrations of 16 versus 64 mg/liter (P Ͼ 0.1, ANOVA). Hypothesis testing revealed that the EC 50 s at 10 8 CFU/ml were 2.81 to 66.5 times greater than those at 10 6 CFU/ml (median, 10.7-fold increase; P ϭ 0.002, F-test); however, no significant differences in E max were observed between the two inocula (P ϭ 0.531, F-test).
DISCUSSION
The introduction of ceftolozane-tazobactam has attracted much interest, with in vitro data providing evidence that this combination may present a promising addition to the therapeutic armamentarium against a range of Gram-negative pathogens, including ␤-lactamase-expressing strains (1-3, 5-8, 18-20) . It is well recognized that appropriate antimicrobial dosing strategies necessitate a solid understanding of PK/PD principles to understand the relationship between the concentration-time profile and antimicrobial activity, allowing the design of regimens that maximize bacterial eradication and minimize the development of resistance. In the present study, the in vitro activities of an array of ceftolozane and tazobactam concentrations were tested alone and in combi- nation in a dynamic fashion over 48 h against four strains of E. coli expressing different ␤-lactamases. Our study design incorporated a wide range of concentrations to ensure that all relevant PD parameters were captured for mathematical modeling purposes in the future.
The ability of inhibitors to inactivate specific ␤-lactamase enzymes varies markedly within and between classes; for tazobactam, irreversible ␤-lactamase inhibition ("suicide inhibition") has mainly been demonstrated against pathogens expressing class A ␤-lactamases, while reduced activity has been reported for those expressing classes B, C, and D (21) . In the present study, however, the time-kill data provide evidence that ceftolozane activity was enhanced by the addition of tazobactam in a concentration-dependent manner, which was observed against all ␤-lactamaseproducing strains at both inocula, irrespective of ␤-lactamase expression ( Fig. 1 and 2 ). This trend was substantiated by analyses of PD parameters, which revealed significantly reduced EC 50 values for all strains, indicating that the potency of ceftolozane increased at both inocula in the presence of increasing tazobactam concentrations. Characteristic differences noted in the time-kill profiles obtained for each strain serve to reinforce the varied extent of inactivation that tazobactam may pose on different ␤-lactamases (21). Notably, a 10.7-fold median increase in EC 50 was observed at the inoculum of 10 8 CFU/ml compared to EC 50 values at 10 6 CFU/ ml; similar trends have been observed for other ␤-lactam agents against ␤-lactamase-producing strains in the presence of a high bacterial load (22) (23) (24) . Mechanistic explanations for the differential PD observed between the two inocula have been hypothesized, including the possible release of larger quantities of ␤-lactamase enzymes from lysed bacteria (25) , cell-to-cell communication, or the decreased presence of active penicillin-binding proteins due to the reduction in bacterial cell wall synthesis at higher bacterial densities (26, 27) . Although the clinical implications of these observations have yet to be understood, consideration may be given to the administration of elevated ceftolozane doses when employed for the treatment of infections that entail a higher bacterial burden.
Interestingly, despite previous suggestions of improved stability of ceftolozane against AmpC ␤-lactamase from Pseudomonas aeruginosa (2, 7, 28) , the exposure of 2890 to ceftolozane monotherapy resulted in extensive regrowth, even at extremely high concentrations (256 mg/liter) far in excess of the MIC (Fig. 1F) . Owing to the relatively stable ceftolozane concentrations used during the time-killing experiments, regrowth was likely characterized by the amplification of ceftolozane-resistant subpopulations. Indeed, the phenomenon of heteroresistance to colistin (29) , vancomycin (30) , and carbapenems (31) has been reported and defined as the presence of a resistant subpopulation of bacteria within a susceptible strain based on MICs. Although heteroresistance has yet to be detected in E. coli, it certainly provides a plausible explanation for the regrowth observed here (Fig. 1F) . Importantly, for strain 2890, the addition of 4 mg/liter tazobactam to regimens with Ն4 mg/liter ceftolozane resulted in bactericidal activity by 24 h at 10 6 CFU/ml (Fig. 1H) , although regrowth at a concentration of 4 mg/liter ceftolozane was observed by 48 h. Increasing the dose of tazobactam further to 16 mg/liter resulted in sustained killing at the ceftolozane concentration of 4 mg/liter up to 48 h (Fig. 1I) . Similarly, the addition of Ն16 mg/liter tazobactam to regimens with Ն64 mg/liter ceftolozane achieved bactericidal activity by 48 h in the ceftolozane-resistant strain 2807 at (16, 32, 33) . Taken together, these results highlight the utility of tazobactam to increase the susceptibility of ␤-lactamase-producing E. coli strains to ceftolozane therapy at both inocula.
Although the %T Ͼthreshold has been identified as the PK/PD index most predictive of the activity of ceftolozane-tazobactam, our results show a clear concentration dependence, with enhanced killing at elevated ceftolozane concentrations. The %T Ͼthreshold was first proposed by VanScoy et al. (12) as the PK/PD index that best described ceftolozane-tazobactam killing in E. coli strains expressing the CTX-M-15 ␤-lactamase (12). Further work with E. coli and Klebsiella pneumoniae strains expressing various ␤-lactamases led to the unifying conclusion that the percentage of time above the ceftolozane-tazobactam MIC ϫ 0.5 is predictive of the combination's efficacy, regardless of the ␤-lactamase expression profile of the pathogen (11) . An in vivo study utilizing a neutropenic mouse model corroborated %T Ͼthreshold as the ideal PK/PD index, and the authors were able to identify the % time above the MIC (%T ϾMIC ) targets required to achieve specific magnitudes of bacterial killing (34) . In the present study, the concentration dependence observed in the time-kill experiments may partially be ascribed to the elevated bacterial burden (10 8 CFU/ml) that exceeded the bacterial load utilized in previous in vitro (10 6 CFU/ml) and in vivo (10 6.2 to 10 7.1 CFU/ml) studies (11, 12, 34) . The static concentrations used in the current investigation may also account for some of the discordance with the results from prior studies. However, previous investigations evaluating the PK/PD of ␤-lactam-␤-lactamase inhibitor combinations have asserted that stoichiometric inhibition of ␤-lactamase enzymes is determined by exposure of the inhibitor over time, which is best predicted by the area under the concentrationtime curve (AUC) (35) . A prior study utilizing piperacillin and tazobactam also found that dose fractionating the administration of both agents while maintaining the same drug exposure did not alter the killing of a TEM-producing strain of E. coli (36) . The activity of ceftolozane-tazobactam may therefore not be completely described by time-dependent killing, and a hybrid index that accounts for the AUC or C max may improve the predictive capability of the %T Ͼthreshold index.
In summary, we systematically described the concentrationeffect relationship of ceftolozane and tazobactam alone and in combination, revealing the ability of ceftolozane-tazobactam to achieve potent bactericidal activity against E. coli strains expressing different types of ␤-lactamase enzymes. While these results are promising, our time-kill studies utilized static concentrations of ceftolozane-tazobactam, making the extrapolation of our results into the clinical setting difficult. To the best of our knowledge, only two studies, by VanScoy et al. (10, 37) , have looked at ceftolozane-tazobactam in a hollow-fiber infection model. Further studies evaluating the performance of the combination regimen against other pathogens containing ␤-lactamase enzymes are needed to completely understand the niche of ceftolozane-tazobactam among other ␤-lactams.
